NCT07912866Completed
Efficacy Of Supplemental L-Arginine in Preventing Preeclampsia in Pregnant Women
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
This study was designed to assess whether daily L-arginine supplementation could prevent preeclampsia in pregnant women at increased risk. Preeclampsia, a pregnancy complication involving high blood pressure and possible organ damage, was the condition of interest. The study hypothesis was that L-arginine supplementation would be more effective than placebo in preventing preeclampsia before delivery. The study was designed as a randomized controlled trial at the Department of Gynaecology and Obstetrics, Bahawal Victoria Hospital, Bahawalpur, Pakistan. Eligible participants were women aged 18-40 years with a single-baby pregnancy at 20 weeks and an increased risk of preeclampsia based on their personal or family medical history. The protocol specified assignment by chance to either daily oral L-arginine supplementation or placebo until delivery. Follow-up visits were scheduled every three weeks during pregnancy and two weeks after childbirth. Assessments included blood pressure, urine testing for protein, and monitoring for side effects. The main outcome was the proportion of women who remained free of preeclampsia until delivery. Other planned assessments included pregnancy complications, delivery outcomes, birth weight, newborn health, and admission to intensive care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 108 (actual)
- First submitted
- 28 Oct 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Quaid-e-Azam Medical College
- NCT number
- NCT07912866
What you commit to
- Study type: Interventional
- Participants enrolled: 108
- From 1 Jul 2025 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The identification of high blood pressure prior to the twentieth week of pregnancy.
- Patients on specific treatment protocols, including anti-oxidant therapy like selenium-rich diets or selenium supplements.
Other illness
- Individuals with history of diabetes mellitus (non-gestational).
- Individuals suffering from renal disease (assessed on history and medical record).
- Women with heart disease diagnosed on history and echocardiography.
- Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) (assessed on history and medical record).
Other
- Patients with known major fetal anomalies (as defined by ultrasound studies.
Who the study is looking for
- Women with age 18-40 years,
- Singleton pregnancy of 20 weeks on ultrasound
- High-risk pregnancy.
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Quaid e Azam Medical College , bahawalpur Coordinator of this site? Confirm its status | Chak Eighty-seven -Twelve Left | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.